<DOC>
	<DOCNO>NCT01702766</DOCNO>
	<brief_summary>Hypothesis : Use Bifidobacterium animalis subsp . lactis effectively prevent common nosocomial ( gastrointestinal respiratory ) infection . Nosocomial infection define infection develop 48 hour admission present incubate admission This study prospective , randomize , double blind , placebo- control parallel study child hospitalize Children 's hospital Zagreb . The study investigate effect supplementation probiotic strain Bifidobacterium animalis subsp . lactis incidence duration gastrointestinal respiratory infection . The test product sachet contain 1 gram powder . The test product contain minimum 1 billion CFU ( colony form unit ) probiotic per serve . The placebo product identical product except absence probiotic . The study include intervention period last length hospital stay . The study product consume daily morning together breakfast . The consumption study product take surveillance physician . Data infection diagnose physician record CRF . The incidence infection analyze base information record CRF .</brief_summary>
	<brief_title>Bifidobacterium Animalis Subsp . Lactis Lowering Risk Common Infections Hospitalized Children</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>Children hospitalize Department Paediatrics , Children 's Hospital Zagreb Age 1 year 18 year Signed informed consent parent Immunodeficiency Infants neonatal period 1 year age Rehospitalisation ( readmission hospital within one month ) Receiving probiotic /or prebiotic product prior enrolment ( 2 week prior hospitalization ) Neoplasms Severe chronic disease Hospitalization shorter 3 day</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>